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RETAINED SENSITIVITY TO CYTOTOXIC PYRIMIDINE
NUCLEOSIDE ANALOGS IN THYMIDINE KINASE 2 DEFICIENT
HUMAN FIBROBLASTS
Mia Bjerke,1 Nicola Solaroli,1 Nicole Lesko,1 Jan Balzarini,2
Magnus Johansson,1 and Anna Karlsson1
1Department of Laboratory Medicine, Karolinska Institute, Huddinge, Sweden
2Rega Institute for Medical Research, Leuven, Belgium
 Thymidine kinase 2 (TK2) is a mitochondrial deoxyribonucleoside kinase that phosphorylates
several nucleoside analogs used in anti-viral and anti-cancer therapy. A fibroblast cell line with
decreased TK2 activity was investigated in order to obtain insights in the effects of TK2 deficiency on
nucleotide metabolism. The role of TK2 for the sensitivity against cytotoxic nucleoside analogs was
also investigated. The TK2 deficient cells retained their sensitivity against all pyrimidine nucleoside
analogs tested. This study suggests that nucleoside analog phosphorylation mediated by TK2 may
be less important, compared to other deoxyribonucleoside kinases, for the cytotoxic effects of these
compounds.
Keywords Nucleoside kinase; nucleoside analog; mitochondrial DNA
1. INTRODUCTION
Pyrimidine nucleoside analogs are used for treatment of viral infections
and as chemotherapy of cancer. The nucleoside analogs are imported from
the extracellular space by nucleoside transporter proteins and phosphory-
lated to the mono-, di-, and tri-phosphate forms within the cells.[1] Phos-
phorylation of nucleoside analogs is required for pharmacological effects
since the phosphorylated nucleoside analogs inhibit enzymes involved in
deoxyribonucleotide metabolism or interfere with cellular or viral DNA
replication. The rate-limiting step in nucleoside analog phosphorylation is
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2 M. Bjerke et al.
catalyzed by nucleoside kinases. Pyrimidine deoxyribonucleoside analogs
can be phosphorylated by thymidine kinase 1 (TK1), thymidine kinase 2
(TK2), or deoxycytidine kinase (dCK).[1,2] The substrate specificity of TK1
and dCK does not overlap, whereas TK2 shares several substrates with both
these enzymes. The deoxyribonucleoside kinases differ in tissue expression,
cell cycle regulation, and subcellular localization. TK1 is cell cycle regulated
and only expressed in S-phase cells, whereas TK2 and dCK are constitutively
expressed throughout the cell cycle. TK1 and dCK are both located in
the cytosol/nuclear compartment and TK2 is located in the mitochondrial
matrix.[3–5]
Several pyrimidine nucleoside analogs used in anti-viral therapy such
as 3′-azido-2′,3′-dideoxythymidine (AZT) and 2′,3′-dideoxycytidine (ddC),
cause severe adverse effects by interfering with mitochondrial DNA
(mtDNA) replication.[6] The nucleoside analog triphosphates are incor-
porated into mtDNA by the mitochondrial DNA polymerase γ and cause
DNA chain termination resulting in mtDNA depletion.[7] Although several
of these nucleoside analogs are substrates of TK1 or dCK as well as of
mitochondrial TK2,[1] the role of mitochondrial TK2 for phosphorylation
of these nucleoside analogs has remained unclear.
Inherited TK2 deficiency is a rare autosomal disease that causes mi-
tochondrial DNA depletion syndrome (MDS) with symptoms of severe
myopathy.[8,9] The myopathy presents in infancy and is fatal due to respi-
ratory chain dysfunction.[10,11] In the present study a fibroblast cell line
with TK2 deficiency has been investigated.[12] The cytotoxicity of several
pyrimidine nucleoside analogs was studied to elucidate the importance of
TK2 for the cytotoxic effects of these compounds.
2. MATERIALS AND METHODS
2.1. Genotyping
Two pairs of primers were designed to amplify exon 3 and exon 6 of
the TK2 deficient fibroblast cell line as well as the two control cell lines.
Each forward primer contained the M13 universal sequence in the 5′, while
each reverse primer contained M13 reverse sequence. The primers for
exon 3 amplification were: 5′-TGTAAAACGACGGCCAGTTGGTTACAT
GAGCCCTTTCC-3′ and 5′-CAGGAAACAGCTATGACCAAGCTTTCTCC
GCTTCCTTC-3′. The primers for exon 6 amplification were: 5′-TGTAAAA
CGACGGCCAGTACATTTCTCAAGGCCTCCTG-3′ and 5′-CAGGAAACA
GCTATGACCGAGGATTCGTGGCTGTTTGT-3′. The polymerase chain
reaction (PCR) was prepared following the protocol of the AmpliTaq Gold
DNA Polymerase (Applied Biosystems, Foster City, CA, USA) with 100 ng of
genomic DNA as template. The elongation time was set to 1 minute, and
the expected bands (244 bp for exon 3 and 336 bp for exon 6) were excised
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Retained Sensitivity to Nucleoside Analogs in Tk2 Deficient Cells 3
from the gel and purified with MiniElute gel extraction kit (Qiagen, Venlo,
The Netherlands). The bands were sequenced in both strands using M13
universal and M13 reverse primers.
2.2. Expression and Purification
The wildtype TK2 and the TK2 R130W mutant proteins were expressed
in E. coli as fusions protein to glutathione S-transferase. The plasmids
were transformed into Rosetta (DE3; Novagen, Madison, WI, USA) and
single colonies were inoculated into LB medium supplemented with 100
µg/ml ampicillin. The bacteria were grown at 37◦C and protein expres-
sion was induced at OD600 ≈ 0.8 with 1 mM isopropyl-1-thio-β-D-galacto-
pyranoside for 12 hours at 27◦C. The expressed proteins were purified using
glutathione-sepharose 4B (Amersham Pharmacia Biotech, Piscataway, NJ,
USA) as described by the producer. The purity of the recombinant proteins
were verified by sodium dodecyl sulfate−polyacrylamide gel electrophoresis
(Phast system, Amersham Pharmacia Biotech) and the protein concentra-
tions were determined with the Bradford Protein Assay (Bio-Rad, Hercules,
CA, USA) using bovine serum albumin as the concentration standard.
2.3. Enzyme Assays
The activity of the purified recombinant enzymes was assayed in a 50
µl reaction mixture containing: 50 mM Tris-HCl pH 7.6, 0.1 mg/ml BSA,
2.5 mM ATP, 5 mM MgCl2, 5 mM dithiothreitol and 10 µM [methyl-3H]-
thymidine (Moravek Biochemicals, Brea, CA, USA) or 0.2 µM [5′-3H]-5-
(Bromovinyl)-2′-deoxyuridine (Moravek Biochemicals), and thymidine (10
µM to 10 mM) or BVDU (10 µM to 500 µM). The samples were incubated
30 minutes at 37◦C, and every 10 minutes 10 µl aliquots were spotted on
Whatman DE-81 filter paper disks. The filters were dried 1 hour and then
washed 3 times for 5 minutes in 5 mM ammonium formate and once in
sterile water. The filter bound nucleoside monophosphates were eluted
in 500 µl of 0.1 M HCl and 0.1 M KCl and the radioactivity quantified
by scintillation counting. The Michaelis-Menten constants were calculated
using the GraphPad Prism software (GraphPad Software, La Jolla, CA, USA).
The substrate specificity of the purified enzymes was assayed by thin
layer chromatography (TLC). The assay was performed in 50 mM Tris−HCl
pH 7.6, 0.5 mg/ml BSA, 5 mM MgCl2, 5 mM DTT, 10 mM ATP, 15 µCi
[γ -32P]ATP (Amersham Pharmacia Biotech), 1 mM of each substrate and 2
µg of recombinant human TK2 and TK2 R130W respectively. The samples
were incubated for 30 minutes at 37◦C. An amount of 2 µl of the reaction
mixtures were spotted on polyethyleneimine-cellulose F TLC sheets (Merck,
Whitehouse Station, NJ, USA). The nucleoside monophosphates were sep-
arated in a buffer containing NH4OH:isobutyric acid:dH2O (1:66:33) and
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4 M. Bjerke et al.
the nucleoside diphosphates were separated in 0.5 M ammonium formate
pH 3.5. The sheets were autoradiographed using phosphoimaging plates
(BAS-1000, Fujix, Kyoto, Japan).
2.4. Cell Culture
Among a collection of human fibroblast cell lines at our department,
one cell line was identified as TK2 deficient whereas two other cell lines
with unaltered TK2 activity were selected as control cells. The three cell
lines selected for the present study have an unrelated origin. The fibroblast
cell lines were cultured in Dulbecco’s modified eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal calf serum (Gibco, Life Tech-
nologies, Paisley, UK), 120 U/ml penicillin and 0.12 mg/ml streptomycin
in a humidified atmosphere with 5% CO2 at 37◦C. Cell culture media were
renewed every 3–4 days.
Cell proliferation assays to determine the acute toxicity of nucleoside
analogs were performed on ≈ 1.0 × 105 cells/ml seeded in 200 µl wells
of 96 well microtiter plates in the presence of serial dilutions of the test
compounds. The cells were cultured at 37◦C for 120 hours and the cell
number was determined by use of a Coulter counter type ZM (Coulter
Electronics, Fullerton, CA, USA). The cells were stained with MitoTracker
red (Molecular Probes, Invitrogen, Carlsbad, CA, USA).
2.5. Quantification of mtDNA
To determine the delayed toxicity of the nucleoside analogs 3′-azido-
2′,3′-dideoxythymidine (AZT) and 2′,3′-dideoxycytidine (ddC) the cells were
cultured for 14 days in the presence of different concentrations of these
nucleoside analogs. Cells cultured in 0.25 mg/ml of ethidium bromide
(EtBr) were used as control. At day 7 and 14 respectively the cells were
harvested and and genomic DNA was extracted from 1 × 106 cells using
the Easy DNA extraction kit (Invitrogen, Carlsbad, CA, USA). mtDNA levels
were quantified by real-time quantitative PCR as described.[13]
Southern blot analysis of mtDNA was performed on 5 µg DNA digested
with BamH1 separated on a 0.8% agarose gel. The gel was blotted onto a
Hybond N+ nylon membrane (Amersham). The filter was hybridized with
[32P]dCTP-labelled mtDNA probe (a fragment of 1484 bp) (Perkin-Elmer
Applied Biosystems, Waltham, MA, USA). Prehybridization, hybridization,
and washing were performed following the provider’s instructions. The
washed membrane was developed and analyzed.
2.6. Phosphorylation Assay
Protein was extracted from 2 × 106 cells by adding 200 µl of an
extraction buffer containing 50 mM Tris-HCl pH 7.6, 20% glycerol, 0.5%
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Retained Sensitivity to Nucleoside Analogs in Tk2 Deficient Cells 5
NP40, 2 µM DTT, 0.05 mg/ml PMSF, and 5 mM benzamidine. The cells were
then frozen/thawed three times. After centrifugation the supernatants were
kept at −80◦C. The activity of TK2 was measured in the protein extracts.
Protein was added to a 100 µl reaction mixture containing: 50 mM Tris-HCl
pH 7.6, 0.5 mg/ml BSA, 5 mM ATP, 5 mM MgCl2, 2 mM dithiothreitol and
2.5 µM [5′-3H]BVDU (Amersham Pharmacia Biotech). The samples were
incubated for 60 minutes at 37◦C and, every 15 minutes 10 µl aliquots were
spotted on Whatman DE-81 filter paper disks. The filters were dried for 1
hour and then washed 3 times for 5 minutes in 5 mM ammonium formate.
The filter-bound nucleoside monophosphates were eluted in 500 µl of 0.1 N
HCl and 0.1 N KCl and the radioactivity quantified by scintillation counting.
2.7. Nucleotide Incorporation Assay
The cells were incubated for 48 hours in DMEM with 0.5% fetal bovine
serum to stop cell proliferation. The cells were then treated for 1, 2 and
4 hours with 1µM [methyl-3H]Thymidine (Moravek Biochemicals). They
were trypsinized and centrifuged and the pellet was incubated on ice for 1
hour with 10% trichloroacetic acid (TCA). After another centrifugation the
pellet were resuspended in 500 µl of 0.5% sodium dodecyl sulphate (SDS)
and 0.5 M of NaOH and transferred to a scintillation tube. Thereafter, 3 ml
ready safe liquid scintillation reagent was added and the radioactivity was
measured by scintillation counting.
3. RESULTS
A recombinant TK2 enzyme was expressed based on the sequence
information obtained from the cell line identified with TK2 deficiency
described in the methods section. Sequencing of exon 3 of the TK2 gene
showed an insertion of 2 bases (C and G) in one allele resulting in a frame
shift stop mutation and a truncation of the protein lacking amino acids in
the C-terminal end. The remaining truncated polypeptide did not contain
the nucleotide binding domain and was subsequently completely devoid of
enzymatic activity (data not shown). In exon 6 of the other allele, there was
a point mutation (C to T) resulting in a replacement of arginine 130 by
tryptophane (R130W) (Figure 1). It was concluded that the remaining TK2
activity in the cell line was derived from the TK2 R130W mutant and thus
this enzyme was further characterized. The TK2 R130W mutant enzyme and
a wildtype control were expressed in E. coli and investigated for substrate
recognition and catalytic activity.
The kinetic properties of the recombinant protein were determined,
comparing the R130W TK2 mutant to wildtype TK2 (Table 1). The TK2
R130W mutant showed a 5-fold increase of Km using thymidine as substrate,
while there was no significant change in Km for the nucleoside analog
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TABLE 1 Michaelis-Menten kinetic properties (mean ± SD, n = 3) of thymidine
and 5-(2-bromovinyl)-2′-deoxyuridine (BVDU) phosphorylation by TK2 wildtype
and R130W recombinant proteins
Km (µM) V max (pmol/mg/min) V max/Km
Thymidine
wt 14.7 ± 2.8 1020 ± 36 69
R130W 75.2 ± 4.8 630 ± 84 8
BVDU
wt 20.1 ± 3.7 2900 ± 78 144
R130W 21.8 ± 2.8 257 ± 59 12
5-(bromovinyl)-2′-deoxyuridine (BVDU). On the contrary the V max reduc-
tion was 11-fold lower when the substrate was BVDU while only slightly
reduced for thymidine. The V max/Km ratio demonstrated a reduction of
enzyme efficacy of the TK2 R130W mutant compared to wildtype TK2 of
∼8-fold for thymidine and ∼12-fold for BVDU. The TK2 R130W mutant
enzyme showed a marked decrease in phosphorylation of the nucleoside
analogs AZT, BVDU, 1-β-D-arabinofuranosylthymine (araT) and 1-β-D-
arabinofuranosylcytosine (araC) as compared to the wildtype TK2 enzyme
(Figures 2A and 2B). Accordingly, the R130W mutation in TK2 decreased
the ability of the enzyme to phosphorylate dThd as well as several nucleoside
analogs (Figure 2C).
The TK2-deficient fibroblast cell line with the TK2 R130W mutant
(TK2− cells) and two human fibroblast control cell lines (TK2+-1 and
FIGURE 1 Sequences of exon 3 and exon 6 of the TK2 deficient cell line. The sequence of exon 3 shows
a frameshift mutation resulting in a truncated protein (left) and exon 6 shows a non synonymous point
mutation (C to T), resulting in a replacement of arginine-130 to tryptophane (R130W) (right).
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Retained Sensitivity to Nucleoside Analogs in Tk2 Deficient Cells 7
FIGURE 2 (A) Phosphorylation of nucleoside analogs by recombinant wildtype TK2; (B) and mutant
R130W TK2 enzyme. The 32P-phosphorylated nucleoside analogs were detected by thin-layer chro-
matography analysis (arrows indicate nucleoside monophosphate products); (C) Phosphorylation rate
of nucleoside analogs relative to dThd phosphorylation catalyzed by wildtype TK2 (black bars) or mutant
R130W TK2 (white bars).
TK2+-2 cells) were exponentially grown in culture. The three cell lines
had similar morphology and the TK2− cells exhibited rapid growth with
a doubling time that was comparable with one of the two TK2+ cell lines
(Figure 3A). The TK2− fibroblast cells showed a normal distribution of
the mitochondria when the cells were stained with Mitotracker (Figures
3B and 3C). The phosphorylation of BVDU in protein extracts from the
different cell lines was determined and showed that the BVDU phospho-
rylation rate was decreased in the TK2− cells compared to the two TK2+
cell lines (Figure 4A). The TK2 deficiency was confirmed by measuring
thymidine incorporation in resting cells. Almost no incorporation of 3H-
dThd could be detected in the TK2− cells as compared to the TK2+ cells
(Figure 4B).
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8 M. Bjerke et al.
FIGURE 3 (A) Growth rate of TK2+ and TK2− fibroblasts; mitochondrial DNA stained with Mitotracker
in (B) TK2+-1 fibroblast cell line; (C) TK2− fibroblast cell line.
TK2 deficiency is associated with mtDNA depletion in patients and in
a mouse model.[8,9,14] Southern blot analysis of BamH1 digested mtDNA
from the cell lines showed a major band of 16.7 kbp corresponding to the
expected size of the mitochondrial genome. The analysis also showed that
there were no major deletions in the mtDNA (Figure 5A). The intensity of
the mtDNA band from the TK2− cell lines was several-folds stronger than
the band from the TK2+ cells, suggesting that the cells may have increased
levels of mtDNA compared to the control cells. Real-time PCR analysis was
used to quantify the level of mtDNA in the cell lines and these experiments
confirmed that the TK2− cell had a slightly increased mtDNA copy-number
compared to the other two cell lines (Figure 5B). The mtDNA levels in the
cells cultured in the presence of the nucleoside analogs AZT and ddC were
also studied (Figure 6). The level of mtDNA in TK2+-2 and TK2− remained
unchanged both after 7 as well as 14 days when cultured in 100 and 500 µM
of AZT respectively. The mtDNA level in the cells cultured in the presence
of 20, 50, and 100 µM of ddC, respectively, showed a 90–97% decrease in all
the cell lines at day 14. EtBr was used as control (0.25 µg/ml) and showed a
3-fold decrease in mtDNA in all cells lines at day 14.
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Retained Sensitivity to Nucleoside Analogs in Tk2 Deficient Cells 9
FIGURE 4 (A) Phosphorylation of BVDU in protein extracts from the different cell lines (mean ± SD;
p < 0.05); (B) 3H-dThd incorporation in non-proliferating TK2+-2 and TK2− fibroblast cell lines.
The sensitivity of the TK2+ and TK2− cell lines towards several pyrim-
idine nucleoside analogs was determined (Table 2). All three cell lines
were highly sensitive to dFdC and FdUrd suggesting that dCK activity
determines the toxicity of dFdC and that TK1 is the major contributing
FIGURE 5 (A) Southern blot analysis of BamH1 digested mtDNA from the cell lines; (B) RT-PCR
quantification of mtDNA levels relative to nuclear DNA levels in wildtype TK2+-2 and TK2 deficient
fibroblast cell line (mean ± SD; p < 0.05).
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10 M. Bjerke et al.
TABLE 2 Sensitivity (IC50; mean ± SD) of TK2+ and TK2− fibroblast cell lines to
nucleoside analogs. araA, 9-β-D-arabinofuranosyladenine; araT,
1-β-D-arabinofuranosylthymine; AZT, 3′-azido-2′,3′-dideoxythymidine; Bv-araU,
1-β-D-arabinofuranosyl-5-(E -2-bromovinyl)uracil; BVDU,
5-(2-bromovinyl)-2′-deoxyuridine; dFdC, 2′,2′-difluorocytidine; ddC,
2′,3′-dideoxycytidine; FdUrd, 5-fluoro-2′-deoxyuridine
IC50 (µM)
TK2+-1 TK2+-2 TK2−
araA 105 ± 22 50 ± 18 54 ± 32
araT 98 ± 67 56 ± 18 81 ± 26
AZT ≥ 500 240 ± 97 287 ± 213
Bv-araU > 500 > 500 > 500
BVDU 310 ± 269 154 ± 0 289 ± 64
dCyd > 500 ≥ 500 468 ± 46
dThd 473 ± 38 258 ± 121 236 ± 200
dFdC 0.0062 ± 0.0017 0.0030 ± 0.0002 0.0036 ± 0.0008
ddC 186 ± 58 38 ± 30 43 ± 12
FdUrd 0.28 ± 0.09 0.48 ± 0.44 0.42 ± 0.33
enzyme for FdUrd toxicity. The two TK2+ control cell lines differed for
nucleoside analogs sensitivity where the TK2+-2 cells showed an up to 4-fold
higher sensitivity to several of the investigated compounds than the TK2+-1
cell line. The sensitivity of TK2− cells to the toxicity of the nucleoside
analogs was similar to the TK2+-2 cells and the TK2-deficient cells did not
show decreased sensitivity to any of the investigated nucleoside analogs.
Accordingly, there was no indication that loss of TK2 activity would alter
the cell sensitivity towards the compounds investigated.
FIGURE 6 RT-PCR quantification of mitochondrial DNA levels relative to nuclear DNA levels in wildtype
TK2+-2 and TK2 deficient fibroblast cell line cultured in the presence of different concentrations of AZT,
ddC and EtBr, respectively.
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4. DISCUSSION AND CONCLUSION
Mitochondrial TK2 investigated in vitro phosphorylates several pyrimi-
dine nucleoside analogs used in anti-cancer and anti-viral therapy.[15] The
nucleoside analogs are in addition to recognizing TK2 also substrates of
either TK1 or dCK. The importance of the in vivo TK2-mediated nucleoside
analog phosphorylation in mitochondria has been unclear. A fibroblast
cell line with approximately 8-fold decreased TK2 activity from a patient
with TK2 deficiency was investigated. The TK2 deficiency was confirmed by
measuring the BVDU phosphorylation in cell extracts as well as by deter-
mining the kinetic properties for both thymidine and BVDU using purified
recombinant R130W mutated TK2. BVDU is often used as a selective marker
for TK2 activity in living cells due to its high recognition by TK2.[16] The
incorporation of 3H-dThd in resting cells were also measured to confirm
a reduced TK2 activity in the mutant cells. The activity of the nucleoside
kinase TK1 is dominating in proliferating cells and TK2 represents only a
fraction of the total cellular TK levels. However, when the cells are resting
TK1 is almost undetectable and TK2 is the only thymidine phosphorylating
kinase.[3]
It was shown that the sensitivity of the TK2 deficient cells towards
the nucleoside analogs tested was at least as high as the sensitivity of two
wildtype control fibroblast cell lines. The control cells used in this study
were fibroblast cell lines from two different age-matched patients. Although
the wildtype cells differed in growth rate, the sensitivity to nucleoside
analogs was comparable between the three cell lines. These findings suggest
that TK1 and dCK are more important than TK2 for nucleoside analog
phosphorylation and induction of acute cytotoxicity in our cell models.
However, the nucleoside analog cytotoxicity was studied in exponentially
growing dividing cells that express high levels of TK1 during the S-phase of
the cell cycle. Since TK1 is not present in resting cells it is possible that
TK2 may be more important for the delayed nucleoside analog toxicity
observed in certain cells. Previous studies have suggested that nucleoside
analogs phosphorylated in the mitochondrial matrix become trapped in this
subcellular compartment and that the intra-mitochondrial phosphorylation
of nucleoside analogs could be an important determinant for the eventual
mitochondrial toxicity of some nucleoside analogs.[17] However, subsequent
studies showed that deoxyribonucleotides and phosphorylated nucleoside
analogs can be transported across the mitochondrial membrane.[18] Ac-
cordingly, nucleoside analogs phosphorylated in the mitochondrial matrix
by TK2 may also be exported to the cytosolic/nuclear dNTP compartment
to exert their pharmacological effects. This is supported by the finding in
the present study that the effect of ddC on mtDNA levels was similar in all
cell lines investigated indicating that ddC is phosphorylated by dCK and
subsequently transported into the mitochondria.
D
o
w
n
lo
ad
ed
 B
y:
 [
Re
ga
 I
ns
ti
tu
te
 f
or
 M
ed
ic
al
 R
es
ea
rc
h]
 A
t:
 1
1:
17
 1
9 
Ap
ri
l 
20
10
12 M. Bjerke et al.
Patients with inherited TK2 deficiency show a tissue specific mtDNA
depletion with decreased levels in muscle cells whereas other investigated
organs such as blood and skin, show normal mtDNA levels.[19] Dividing
fibroblast also import dNTPs from the cytosol and this may explain why any
mtDNA depletion was not observed in these cell lines. This is consistent with
studies on fibroblasts derived from a patient with dGK deficiency that also
exhibited normal mtDNA levels.[19]
Subsequent questions to be addressed involve effects of cell cycle phases
on mtDNA synthesis in cells deficient of TK2. The present TK2 deficient
cells have a low but maybe significant residual TK2 activity that may result in
phenotypic changes only when TK1, and other dTTP or dCTP contributing
enzymes, are expressed at very low levels. Considering the severe phenotypic
alterations in patients with reported TK2 deficiency it is clear that there
are large tissue and organ specific differences of the importance of TK2
for cellular functions. The fibroblast cultures used in the present study
demonstrates an example of cells where the contribution of TK2 for normal
cell growth seems very low. It is likely that compensatory enzymes must be
present in cultured fibroblasts for the synthesis of deoxyribonucleotides for
mitochondrial DNA. The challenge will be to understand and use these
compensatory mechanisms to treat mitochondrial DNA deficiency in cells
that are dependent on TK2 for their survival.
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